Regeneron Pharmaceuticals, Inc. (REGN) Yield on Cost (YOC): 0.59%
The yield on cost (YOC) for Regeneron Pharmaceuticals, Inc. (REGN) is 0.59%.
REGN Yield on Cost (YOC) Metrics
YIELD ON COST (YOC)
0.59%
Forward Yield on Cost Projections
If you buy REGN today at the current stock price of $616.18 with a yield of 0.59% and dividends continue to grow at the historical rate (8.0% CAGR), your YOC would be:
Current Yield
0.59%
YOC in 3 Years
N/A
YOC in 5 Years
N/A
YOC in 10 Years
N/A
Interactive Yield on Cost Calculator
Project custom investment returns for Regeneron Pharmaceuticals, Inc. (REGN) based on your custom cost basis.
Starting Yield
0.59%
Ending YOC
1.87%
Year 15 Dividend
$11.55
Cum. Dividends Recd.
$106.74
| Year | Projected Div. / Share | YoY Dividend Hike | Yield on Cost (YOC) | Total Dividends Recd. |
|---|---|---|---|---|
| Initial | $3.64 | — | 0.59% | $0.00 |
| Year 1 | $3.93 | +8.00% | 0.64% | $3.93 |
| Year 2 | $4.25 | +8.00% | 0.69% | $8.18 |
| Year 3 | $4.59 | +8.00% | 0.74% | $12.76 |
| Year 4 | $4.95 | +8.00% | 0.80% | $17.71 |
| Year 5 | $5.35 | +8.00% | 0.87% | $23.06 |
| Year 6 | $5.78 | +8.00% | 0.94% | $28.84 |
| Year 7 | $6.24 | +8.00% | 1.01% | $35.08 |
| Year 8 | $6.74 | +8.00% | 1.09% | $41.81 |
| Year 9 | $7.28 | +8.00% | 1.18% | $49.09 |
| Year 10 | $7.86 | +8.00% | 1.28% | $56.95 |
| Year 11 | $8.49 | +8.00% | 1.38% | $65.44 |
| Year 12 | $9.17 | +8.00% | 1.49% | $74.60 |
| Year 13 | $9.90 | +8.00% | 1.61% | $84.50 |
| Year 14 | $10.69 | +8.00% | 1.74% | $95.19 |
| Year 15 | $11.55 | +8.00% | 1.87% | $106.74 |
Yield on Cost (YOC) Formula
Formula: Yield on Cost = Annual Dividend / Original Purchase Price × 100
Inputs shown in the projection:
- Original purchase price.
- Annual dividend per share at the starting point.
- Assumed annual dividend growth rate.
- Projected annual dividend divided by original purchase price.
Note: Forward projections assume dividends continue to grow at the designated growth rate. Actual dividend payments are declared by corporate boards and are subject to change.
Regeneron Pharmaceuticals, Inc. Yield on Cost (YOC) Formula & Definition
Yield on Cost shows the dividend yield based on your original purchase price. As dividends grow, your YOC increases even if the market yield stays the same.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Regeneron Pharmaceuticals, Inc. Yield on Cost (YOC) FAQ
- What is the yield on cost (YOC) for Regeneron Pharmaceuticals, Inc. (REGN)?
- The yield on cost (YOC) for REGN stock is 0.59%.
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Leonard S. Schleifer